Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

समान संसाधन

• Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
  द्वारा: Zi‐Ting Chang, और अन्य
  प्रकाशित: (2025-07-01)
• Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
  द्वारा: Qi-An Wang, और अन्य
  प्रकाशित: (2025-03-01)
• The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
  द्वारा: Hsu, Ping-Chih, और अन्य
  प्रकाशित: (2020)
• Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
  द्वारा: Yan-Jei Tang, और अन्य
  प्रकाशित: (2024-01-01)
• Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study
  द्वारा: I-Lin Tsai, और अन्य
  प्रकाशित: (2025-06-01)